Brind.
  1. Innovent Biologics partnered with Spero Therapeutics Inc. to advance the development of IBI355.

HCRx buys into Utebzi milestones and royalties, GSK grants exclusive license for Utebzi, and Spero in-licenses SP001 from Innovent Biologics.

1 report, 1 independent Updated Jul 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

HCRx buys into Utebzi milestones and royalties, GSK grants exclusive license for Utebzi, and Spero in-licenses SP001 from Innovent Biologics.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped